Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Manya Magnus, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David BurnsAlex R. Rinehart, David Margolis, William R. Spreen, Myron S. Cohen, Marybeth McCauley, Joseph J. Eron
Dive into the research topics of 'Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial'. Together they form a unique fingerprint.